FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer

Stopped Higher then expected Gr3 GU/GI toxicity

Conditions

• Prostate Cancer

Interventions

• RADIATION: Stereotactic Body Radiation
• DRUG: Luteinizing Hormone Releasing Hormone (LHRH) Agonist

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's